CG Oncology shares are down about 3% in Wednesday trading (April 22, 2026), with traders pointing to supply/overhang concerns tied to recent insider-selling disclosures rather than any fresh trial readout or company press release today. A Form 4 disclosed an open-market sale of 15,600 shares executed on April 17, 2026 under a Rule 10b5-1 plan, and the company’s filings page also shows a Form 144 filed April 17, 2026 signaling an intent to sell shares received via option exercises—both of which can pressure sentiment in a momentum biotech name even when sales are planned. (stocktitan.net)

The dip is happening after CGON rallied strongly in recent days as bullish research updates circulated, including a widely shared April 18 note referencing a raised price target. When a stock is extended after a catalyst-driven move, incremental selling signals—especially insider-related—often trigger profit-taking and a quick reset in price. (defenseworld.net)

Near-term focus remains on the company’s clinical and regulatory cadence, particularly the expected topline timing for the Phase 3 PIVOT-006 study in intermediate-risk NMIBC that management has guided to the first half of 2026. Separately, investors continue monitoring financing/dilution risk because CG Oncology previously expanded its at-the-market equity offering capacity to up to $550 million, which can add perceived supply if the company taps it into strength. (investing.com)